Inventiva Pharma

Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. Its lead candidate, lanifibranor, is a pan-PPAR agonist in Phase 3 trials for NASH/MASH with breakthrough therapy designation from the FDA. The company has built an extensive proprietary molecule library and wholly-owned R&D capabilities inherited from Abbott, Solvay, and Fournier.